FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:205-207 January 13, 2005 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Yki-Järvinen, H. PubMed Citation

To the Editor: In her otherwise excellent review of thiazolidinediones, Dr. Yki-Järvinen (Sept. 9 issue)¹ states that "the effects of rosiglitazone or pioglitazone on the size of LDL [low-density lipoprotein] particles have not been studied in a double-blind, placebo-controlled trial." That is not quite the case. In a double-blind, randomized trial of pioglitazone as compared with placebo in nondiabetic patients with normolipidemia and hypertension, pioglitazone increased LDL particle size.² Furthermore, in two open-label studies involving patients with type 2 diabetes, the size of LDL particles was increased by rosiglitazone, as compared with placebo,³ and by pioglitazone, as compared with gliclazide.⁴

. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.